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Abstract: 
 
ABC (ATP Binding Cassette) transporters carry out many vital functions and are involved in 
numerous diseases, but study of the structure and function of these proteins is often hampered by 
their large size and membrane location. Membrane protein purification usually utilises detergents 
to solubilise the protein from the membrane, effectively removing it from its native lipid 
environment. Subsequently lipids have to be added back and detergent removed to reconstitute 
the protein into a lipid bilayer.  We present here the application of a new methodology for the 
extraction and purification of ABC transporters without the use of detergent, instead using a 
styrene maleic acid co-polymer (SMA). SMA inserts in a bilayer and assembles into discrete 
particles, essentially solubilising the membrane into small discs of bilayer encircled by polymer, 
termed SMA lipid particles (SMALPs). We show that this polymer can extract several eukaryotic 
ABC transporters; P-glycoprotein (ABCB1), MRP1 (ABCC1), MRP4 (ABCC4), ABCG2 and CFTR 
(ABCC7), from a range of different expression systems. The SMALP encapsulated ABC transporters 
can be purified by affinity chromatography, and are able to bind ligands comparably to those in 
native membranes or detergent micelles.  A greater degree of purity and enhanced stability is seen 
compared to detergent solubilisation. This study demonstrates that eukaryotic ABC transporters 
can be extracted and purified without ever being removed from their lipid bilayer environment, 
opening up a wide range of possibilities for the future study of their structure and function. 
 
 
 
Summary statement: 
 
A styrene maleic acid copolymer can be effectively used to extract and purify large eukaryotic 
transmembrane proteins in the absence of detergents, forming small bilayer discs encapsulating 
the protein, which have great potential for future structure & function studies. 
 
 
Short title: Detergent free purification of ABC transporters 
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Introduction: 
 
The ABC (ATP Binding Cassette) transporter superfamily is found in all organisms from bacteria to 
man, with humans possessing 48 different members [1]. The human transporters are involved in a 
wide range of functions within the body including protection from toxins, metabolism, controlling 
drug distribution in the body, mediating inflammatory responses and transporting lipids [2-5]. 
Several members are involved in causing drug resistance during cancer treatment [6], while others 
are responsible for genetic diseases such as cystic fibrosis and adrenoleukodystrophy [7, 8].  
 
The study of the function and structure of these vital proteins is often hampered by difficulties in 
expressing, extracting and purifying them, as they are large transmembrane proteins requiring a 
lipid bilayer environment. Traditionally purification of membrane proteins such as these has used 
detergent to solubilise the protein from the membrane, thus removing it from its native lipid 
environment. Following purification lipids need to be added back in and detergent removed to 
reconstitute the protein into a lipid bilayer [9]. These reconstituted systems include 
proteoliposomes and planar membranes, and more recently several forms of lipid nano-particles, 
such as bicelles or nanodiscs. The last of these, nanodiscs use membrane associated amphipathic 
peptides to produce small discs of membrane bilayer into which membrane proteins can be 
inserted [10]. Several ABC transporters have been successfully incorporated into nanodiscs, to 
enable many downstream applications [11-14]. However formation of these particles still requires 
detergent solubilisation of the protein before reconstitution into the nanodiscs. Detergent 
solubilisation requires an expensive, trial and error process, and detergents that work well for 
solubilisation may not be compatible with downstream purification or analytical methods [15, 16]. 
 
Here we report the application of a recently developed system for detergent-free extraction of 
ABC transporters from their native membranes using a readily available, biocompatible and 
chemically stable polymer, polystyrene-co-maleic acid (SMA) [17-19]. The polymer inserts into the 
membrane isolating small discs of lipid bilayer that are encircled by the polymer, termed SMA lipid 
particles (SMALPs) [17]. We demonstrate that the polymer is able to effectively solubilise several 
different eukaryotic ABC transporters from a range of different cell types, including mammalian 
cells, insect cells and yeast. ABC transporters within the SMALPs can then be purified using 
standard affinity chromatography methods. We demonstrate that the proteins within the SMALPs 
can bind substrates comparably to those in native membranes or detergent micelles, and we 
characterise the biophysical properties of a SMALP-purified transporter. 
Overall this study demonstrates that the SMALP method can be successfully applied to eukaryotic 
ABC transporters to extract and purify them without ever removing them from their lipid 
environment.  
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Experimental: 
 
SMA preparation 
SMA polymer was prepared as described previously [17]. Briefly, a 10% (w/v) solution of SMA 
copolymer in 1M NaOH was refluxed for 2 hours, allowed to cool to room temperature, then 
dialysed against 20mM Tris buffer pH8 before use.   
 
Cell culture, expression & membrane preparation 
High Five (Trichoplusia ni) insect cells were cultured and infected with recombinant baculovirus to 
express either human P-glycoprotein (Pgp/ABCB1) with a C-terminal 12-His tag or human ABCG2 
with an N-terminal 6-His-tag, and membrane preparations carried out as described previously [15, 
20]. Murine CFTR (cystic fibrosis transmembrane regulator/ABCC7) with two hexa-histidine tags 
and a GFP tag was expressed in Sacchromyces cerevisiae and microsomes prepared as described 
elsewhere [21].  MRP1 (ABCC1) overexpressing drug selected H69AR small cell lung cancer cell line 
was cultured as described previously [22]. MRP1 was also expressed in HEK cells by transfection of 
the pcDNA3.1-MRP1 plasmid [23] using JetPRIME transfection reagent (Polyplus-transfection). 
Plates (10cm) were seeded with 1.3x106 cells transfected after 24 hours with 10µg DNA/plate and 
20µl JetPRIME/plate, and harvested 48 hours later.  ABCG2 was expressed in either MCF7-FLV cells 
cultured as described [24], or following transfection of HEK293T cells with pcDNA3.1_His6_ABCG2 
[25]. MRP4 (ABCC4) with a C-terminal hexa-histidine tag was expressed in HEK cells and 
membranes prepared as described before [26]. MRP4 with a C-terminal hexa-histidine tag was 
also expressed in Spodoptera frugiperda (Sf9) insect cells by infection with a recombinant 
baculovirus. The cDNA for MRP4 was amplified from the pcDNA3.1-MRP4 plasmid [27], and the 
stop codon mutated to an AgeI site by PCR (using the following primers 5’ 
ctacgtcgacgacctaggcatgctgcccg and 3’ ctaagatttagtcgcggccgctcaatggtgatg). The PCR product was 
digested with EcoRI and AgeI and subcloned into a pFastBac-1 vector, resulting in the generation 
of a C-terminally hexahistidine tagged construct. Recombinant baculovirus was formed using the 
Bac-to-Bac kit (Invitrogen). Sf9 cells were maintained at 0.5–2.5×106 cells/mL in shaker cultures at 
28 °C in Insect Xpress media (Lonza) supplemented with 10% (v/v) fetal bovine serum, 100 U/mL 
penicillin, and 100 mg/mL streptomycin. MRP4 expressing baculovirus was amplified by infection 
of Sf9 cells (1×106 cells/mL) at a multiplicity of infection (MOI) of 0.2 for 5 days. MRP4 expression 
in Sf9 cells was achieved by infection with the baculovirus at an MOI of 5 for 3 days. Cells were 
harvested by centrifugation (6000 g, 20 min, 4°C). Whole cell pellets of MCF7-FLV, HEK293T-
ABCG2, H69AR, HEK-MRP1 or Sf9-MRP4 were resuspended in buffer 1 (50 mM Tris pH7.4, 250 mM 
sucrose) supplemented with 0.25 mM CaCl2 and protease inhibitors (Roche or Pierce), then lysed 
by nitrogen cavitation (500 psi, 15 min, 4°C). Cell debris was removed by low speed centrifugation 
(750 g, 20 min, 4°C), then membranes were harvested by ultracentrifugation (100000 g, 20 min, 
4°C). Membranes were resuspended in buffer 1, aliquoted and stored at -70°C for up to 6 months. 
 
SMA extraction 
Membranes were pelleted (100000 g, 20 min, 4°C ) then resuspended in buffer 2 (20 mM Tris pH8, 
150 mM NaCl, 20% (v/v) glycerol) at a final concentration of 30 mg/ml membrane (wet membrane 
weight) and SMA was then added to a final concentration of 2.5% (w/v). Samples were incubated 
at room temperature with gentle shaking for 30 - 60 minutes. Insoluble material was removed by 
centrifugation (100000 g, 20 min, 4°C). For ABCG2 from High Five insect cells only, this method 
was modified slightly in that 1% (w/v) DMPC was also included alongside the SMA, the sample was 
briefly probe sonicated and incubated at 37°C. 
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The insoluble pellet was resuspended in buffer containing 2.5% SDS (w/v) to the same volume as 
the soluble fraction. Samples of both the soluble and insoluble fractions were analysed by 
Western blotting. For most of the proteins studied an anti-His primary antibody was used (R & D 
Systems, typically at 1:500 dilution). For the H69AR samples the primary antibody used was QCRL-
1 (1:2000). For the MCF7-FLV and HEK-ABCG2 samples the primary antibody was Bxp-21 (Merck 
1:2000). In all cases either an anti mouse-Alkaline Phosphatase (Sigma) or anti mouse-HRP (Sigma) 
secondary antibody was used, and visualised using BCIP/NBT colorimetric detection (Sigma) or 
chemiluminescence (Pierce) respectively. The efficiency of solubilisation was quantified from the 
Western blots using densitometry (Image J). 
 
Ni2+-NTA affinity purification 
SMA-solubilised membranes were incubated overnight at 4°C with Ni2+-NTA agarose (Qiagen) 
using 100 μl resin/ml solubilised membrane and slowly rotated. The sample was transferred to a 
gravity flow column (Biorad), washed 5 times with 10 bed volumes (bv) of buffer 2 supplemented 
with 20 mM imidazole, then twice with 10 bv of buffer 2 supplemented with 40 mM imidazole, 
then once with 2 bv of buffer 2 supplemented with 60 mM imidazole. Proteins were eluted using 
buffer 2 supplemented with 120 mM imidazole and 1 bv fractions were collected. Samples of 
various stages of the purification were analysed by SDS-PAGE and visualised by silver staining 
(Pierce). The concentration of purified proteins were determined using Coomassie stained SDS-
PAGE gels as described previously (Rothnie et al 2004 JBC). 
Following purification, samples were concentrated and/or buffer exchanged using centrifugal 
concentrators (Amicon Ultra, Millipore, 30000 MWCO) or subjected to gel filtration spin columns 
to remove imidazole (Biorad, Micro Bio-Spin columns). 
 
Protein A and antibody affinity purification 
Immunoaffinity purification of MRP1 from H69AR membranes using the monoclonal antibody 
QCRL-1 was based on the procedure of Mao et al [28].  Briefly, QCRL-1 ascites fluid (50 µl) was 
diluted to 1ml in buffer 2, then slowly injected on to a protein A AcroSep pre-packed 1ml column 
(PALL).  After incubation at room temperature for 30 min the column was washed 10 x 1 ml with 
buffer 2. SMALP-encapsulated H69AR membranes (1 ml) were then slowly injected on to the 
column. After 30 mins the column was washed 10 x 1 ml with buffer 2. MRP1 was eluted from the 
column using buffer 2 supplemented with the peptide SSYSGDI (ThermoFisher Custom 
Biopolymers) at 3.3 mg/ml, and 1 ml fractions were collected. 
 
Drug binding to Pgp: Fluorescence quenching assay 
Formation of the Pgp:drug complex was studied using the fluorescence quenching method of Liu 
and Sharom [29]. In this method the fluorophore, MIANS, was first used to label cysteine residues 
within the two nucleotide binding domains of ABC transporters. Purified Pgp (100 μg/mL) 
encapsulated within SMALPs was incubated with 20 μM MIANS (Invitrogen) at room temperature 
for 1 h in the dark. DTT (1 mM) was added to quench unreacted fluorophore. Separation of 
MIANS-labelled Pgp-SMALPs from DTT-MIANS was performed by gel filtration chromatography on 
Micro Bio-Spin columns (Bio-rad). Fluorescence quenching of MIANS-labelled Pgp-SMALP (50 
μg/mL) by successive additions of doxorubicin (2.5-25 µM) or verapamil (0.5-12 µM) was 
measured using a Perkin Elmer LS55 fluorimeter at an excitation wavelength of 322±10 nm and 
emission wavelength of 420 nm (λmax). Fluorescence intensities were corrected for dilution, 
scattering and inner filter effect as described previously [29]. Results were analysed by non-linear 
regression using Graphpad Prism (Graphpad Software Inc.) to fit a one-site binding hyperbolic 
equation 1: 
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B = Bmax.[L]/(Kd + [L]) 
 
Drug binding to MRP1: Radioligand binding assay 
The binding of 40 nM 3H-estrone sulphate (Perkin Elmer) to SMALP encapsulated membranes from 
H69AR cells, in the presence or absence of 3 mM GSH was performed as described previously [30].  
However instead of using rapid filtration to separate bound and unbound radioligand, samples 
were instead loaded onto pre-equilibrated Micro Bio-Spin columns (Biorad) and the void volumes 
collected by centrifugation (3000 rpm, 4 min). Scintillation counting was performed using a 
Packard Tri-Carb Liquid Scintillation counter.  
Statistical analysis used a student t-test (GraphPad Prism), and a P<0.05 was considered 
significant. 
 
Drug binding to ABCG2: Pheophorbide A fluorescence 
Binding of SMALP encapsulated ABCG2 to the fluorescent substrate pheophorbide A was detected 
by an enhancement of the fluorescence intensity. Pheophorbide A (10 µM, 1 ml) fluorescence 
emission spectra (640 – 720 nm) were measured at an excitation wavelength of 390±10 nm using 
a Perkin Elmer LS55 fluorimeter. Successive additions (5 – 100 µl) of SMALP encapsulated 
membranes from cells overexpressing ABCG2 were added to the pheophorbide A and incubated 
for 10 minutes before reading the fluorescence spectra again. Specific binding to ABCG2 was 
determined by subtracting the fluorescence intensity obtained when membranes lacking ABCG2 
were added to pheophorbide A, or the ABCG2 membranes were pre-incubated with chrysin (30 
µM) for 10 minutes before addition to pheophorbide A. Results were analysed by non-linear 
regression using Graphpad Prism (Graphpad Software Inc.) to fit equation 1. 
 
Nucleotide binding to Pgp; tryptophan fluorescence quenching 
Binding of nucleotides to purified Pgp within SMALPs was assayed by measuring the quenching of 
intrinsic tryptophan fluorescence as described previously [31]. Briefly, the fluorescence of purified 
Pgp (50 μg/mL) encapsulated within SMALPs was measured using a Perkin Elmer LS55 fluorimeter 
at an excitation wavelength of 290±10 nm and emission wavelength of 330 nm (λmax), and the 
quenching by successive additions of ATP (0.05-2 mM) or the non-hydrolysable fluorescent ATP 
analog, TNP-ATP (9.8-160 µM) was measured. Fluorescence intensities were corrected for dilution, 
scattering and inner filter effect as described previously [29]. Results were analysed by non-linear 
regression using Graphpad Prism (Graphpad Software Inc.) to fit a one-site binding hyperbolic 
(equation 1). 
 
Circular Dichroism Spectroscopy 
Purified Pgp within SMALPs was buffer exchanged into 10 mM Tris pH 8 and concentrated to 0.65 
mg/ml. The circular dichroism spectra was measured using a JASCO J-715 CD spectrophotometer 
with a path length of 0.1 cm at room temperature. The sample was scanned 8 times at 200 
nm/min with a bandwidth of 2 nm. A spectrum of the buffer used in the experiment was used as a 
background.  
 
Analytical Ultracentrifugation 
Purified Pgp encapsulated within SMALPs (0.65 mg/ml) in 10 mM Tris pH 8 was subjected to 
analysis using sedimentation velocity analytical ultracentrifugation. The sample was centrifuged at 
40000 rpm/129000g at 4oC in a Ti50 rotor within a Beckman XL-1 analytical ultracentrifuge 
(Beckman 693 Coulter, Palo Alto, CA, USA). The movement of the protein within the cell was 
monitored using absorbance at 280 nm with 1780 datasets (890 each for absorbance and velocity) 
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being collected over 23 hr 22 min. These data were analysed using SEDFIT [32] and the c(s) and 
c(M) method. Values for Vbar and buffer viscosity and density were calculated using SEDNTERP 
[33]. 
 
Gel filtration 
Purified Pgp encapsulated within SMALPs was run on a Superdex 200 gel filtration column 
(diameter 1.6 cm, column height 55 cm) pre-equilibrated in 20 mM Tris pH8 using an AKTA Purifier 
system. A total of 50 μg in a volume of 0.5 ml 20 mM Tris pH 8 was loaded and the column was run 
at a flow rate of 0.5 ml/min. The column was calibrated using the following standards: Blue 
Dextran, Bovine Serum Albumin, Carbonic Anhydrase, Cytochrome c and Aprotinin (Sigma). 
 
Electron microscopy 
Holey electron microscopy grids (2micron holes, Quantifoil) were prepared of purified Pgp 
encapsulated within SMALPs (1 mg/ml) using an FEI Vitrobot freezing device with plunge freezing 
into liquid ethane. Grids were transferred into a Polara FEG transmission electron microscope and 
maintained at <100K throughout. Areas with sufficiently thin ice were selected at low 
magnification and low dose, and then micrographs were recorded on a 4k x 4k CCD device with 1 
sec exposure and low dose mode imaging conditions. Micrographs were analysed using the 
EMAN2 software package [34], with >8000 particles selected from 20 images.  Strong defocus was 
employed because of the relatively small mass of the particles (defocus range 3.5 to 5.9 micron). 
Correction for the contrast transfer function was carried out and then reference-free classification 
of the particles was performed with unique 32 classes identified. Preliminary 3D structures were 
generated from these classes using a common-lines algorithm and with no symmetry applied. The 
ten low resolution structures were similar and one was selected for refinement of the 3D structure 
using all the single particles. The resolution of the structure after 5 rounds of refinement was 
estimated by Fourier shell correlation between two structures generated from even- and odd-
numbered particles from the data set. The features observed in the final structure corresponded 
to the resolution estimate and with the strong suppression of higher resolution frequencies in the 
images as a result of the need for strong underfocus.  
 
Thermostability 
Pgp was extracted from High Five membranes either using 2.5% (w/v) SMA as described above or 
2% (w/v) octyl-glucoside plus 0.4% (w/v) lipids (4:1 E.coli lipid extract:cholesterol) as detailed in 
[20], then purified by Ni-NTA affinity chromatography as described above, except supplementing 
the buffers with 1.25% (w/v) octyl-glucoside and 0.1% (w/v) lipids. Relative thermostability of the 
purified proteins was monitored using the thiol-reactive flourophore 7-diethylamino-3-(4-
maleimidophenyl)-4-methylcoumarin (CPM, Sigma) as described by Alexandrov et al [35]. CPM is 
essentially non-fluorescent until it reacts with a sulphydryl, thus it can report on the relative 
accessibility of cysteine residues within a protein. As a protein denatures, buried cysteine residues 
become accessible to CPM and the fluorescence signal increases. Purified Pgp (5 µg) was mixed 
with CPM (8 µg/ml) in a total volume of 200 µl. The reaction mixture was heated continuously 
from 10°C - 90°C in increments of 5°C for 2 minutes each.  After 2 minutes at each temperature 
the fluorescence spectra was measured (λex 463±10 nm, λem 410-560±20 nm) in a Perkin Elmer 
LS55 spectrophotometer. The fluorescence intensity (at 470 nm) at each time point was calculated 
as a % of the final fluorescence intensity. The assays were repeated twice for each sample.  
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Results & Discussion: 
 
Extraction of ABC transporters using SMA 
The initial aim was to determine if the SMALP method for extraction of membrane proteins could 
be successfully applied to eukaryotic ABC transporters. For each protein tested membrane 
fractions were prepared and mixed with 2.5% (w/v) SMA for 30-60 mins in the absence of any 
detergent, and insoluble material was removed by centrifugation.  It can be seen in Figure 1 that 
for each of the proteins tested, Pgp, MRP1, MRP4, CFTR and ABCG2, successful extraction was 
observed using SMA. These samples included all of the commonly used cell types for eukaryotic 
ABC transporter expression, namely insect cells, mammalian cells and yeast. It also encompassed a 
range of sizes, with MRP1 at 190 kDa and comprising 17 transmembrane helices, being the largest, 
and both the conventional and reversed topology ABC transporters (i.e. ABCG2 having an NBD-
TMD topology).  The degree of extraction varied but there were no discernible patterns between 
expression systems or protein size.   
For Pgp from High Five insect cells the extraction efficiency with SMA (60%) was comparable to 
previous reports using octyl-glucoside (50%) [20], and the extraction of MRP1 from H69AR cell 
membranes with SMA was comparable to previous reports using the detergent CHAPS (90%) [28]. 
MRP4 expressed in HEK cells is 63% solubilised by SMA whereas when expressed in Sf9 insect cells 
86% is solubilised. The efficiency of MRP4 solubilisation with detergents has not previously been 
reported, therefore we also examined the ability of two commonly used detergents, octyl-
glucuside and dodecymaltoside, to solubilise MRP4 from Sf9 cells (Supplementary Figure 1). Octyl 
glucoside was unable to solubilise MRP4 at all, whereas with DDM 78% of the MRP4 was 
successfully solubilised, which is comparable with the SMA. SMA solubilisation of ABCG2 from 
High Five insect cells was the least efficient at just 36%, however it was previously found that this 
protein is completely insoluble with most detergents and only the long chain foscholine 
detergents were capable of solubilising this protein at all [15]. One possible reason for the 
difficulty in solubilising ABCG2 from High Five cells may be the formation of large oligomers in this 
system [15], which are too large for the lipid discs formed by SMA. However the successful 
solubilisation of ABCG2 from both HEK cells and MCF7-FLV cells show that it is not a feature of 
ABCG2 per se. Interestingly the two most efficient extractions were from drug selected cancer cell 
lines (H69AR and MCF7-FLV) which overexpress transporters due to development of drug 
resistance. It is well known that such drug resistant cell lines display altered membrane 
constituents and properties [36-38], and it seems that this improves the ability of SMA to 
solubilise these transporters. 
 
Purification of ABC transporters encapsulated within SMALPs 
The SMA extracted membranes were then subjected to affinity purification. The SMALPs once 
formed are stable and, unlike detergent solubilised proteins, did not require addition of further 
polymer during the purification procedure. Figure 2 shows silver stained gels for the successful 
purification of each protein. The Pgp, MRP4, CFTR and ABCG2 proteins were purified using single 
step Ni2+-NTA affinity chromatography, whereas MRP1 (which did not have a His-tag) was purified 
using a Protein A column and QCRL-1 antibody. An unexpected outcome of using SMA to solubilise 
the ABC transporters was a much higher degree of purity was obtained following just a single step 
affinity purification than has previously been observed with detergent solubilised proteins, which 
tend to require a second purification step of gel filtration [15, 21, 39] or ion exchange [40].  
To ascertain whether this higher purity using SMA altered the final purified protein yield we 
quantified this and present the data in Supplementary Table 1. For purified Pgp obtained using 
SMA the yield was 631 ± 46 μg per litre of baculovirus infected High Five cell culture which is very 
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similar to that previously reported using octyl glucoside with these same cell membranes (792 ± 
197 μg [20]), and the SMA purified Pgp is significantly more pure than the octyl glucoside 
preparation. Other reports which have used DDM to solubilise Pgp from these membranes have 
used a more stringent purification procedure including gel filtration as well as Ni2+-NTA [41] and 
thus the Pgp produced was highly pure, however this resulted in a significantly lower yield (249 ± 
15 µg/L culture) than that reported here with SMA. The yield of purified ABCG2 using SMA was 116 
± 32 µg/L culture, which is almost 3-fold higher than that previously obtained using foscholine 
(Supplementary Table S1, [15]). For MRP4 the yield of purified protein is relatively low at 35 ± 5 
µg/L culture. This reflects a lower expression level in these cells, but it should be noted that the 
SMA allows an efficient extraction from these low expressing cells and an effective purification, 
whereas when using the detergent DDM with these same membranes the eluted fractions from 
the Ni-NTA column contain a large number of contaminating proteins in levels comparable or 
higher than the MRP4 (Supplementary Figure 3), showing that the SMA method is effective even 
for poorly expressed membrane proteins. 
 
Ligand binding by ABC transporters within SMALPs 
Next we determined whether the structure and function of the ABC transporters was retained 
following SMA extraction by investigating their ligand binding efficiency. A fluorescence quenching 
method devised by Liu & Sharom [29] was used to measure the binding of both doxorubicin (a 
transported substrate) and verapamil (a competitive inhibitor) to purified Pgp within SMALPs 
(Figure 3A). The data were best fitted by a single site binding curve with a Kd for doxorubicin of 9.5 
± 1.5 µM (mean ± sem, n=3) and for verapamil Kd = 2.0 ± 0.4 µM (mean ± sem, n = 4), which 
compare favourably to the previous results for detergent purified Pgp of 4.4 µM for doxorubicin 
and 2.4 µM for verapamil [29]. Furthermore the amplitude of the fluorescence change induced by 
drug binding shows that for both the SMA solubilised and previous detergent solubilised 
preparations the change in intensity for doxorubicin binding is close to twice that observed for 
verapamil [29], showing that the characteristics of doxorubicin and verapamil binding to SMALP-
encapsulated Pgp are consistent with detergent solubilised Pgp. 
The results of an estrone sulphate radioligand binding assay for SMA solubilised H69AR 
membranes in the absence or presence of GSH are shown in Figure 2. It has previously been 
shown that GSH binding causes a conformational change in MRP1 which increases the affinity for 
estrone sulphate binding [30]. SMALP-extracted MRP1 showed the same effect with the presence 
of 3 mM GSH causing a significant increase (2.3-fold, P<0.05) in the binding of estrone sulphate to 
SMALP encapsulated MRP1 which is comparable to that seen in native membranes. 
A fluorescent chorophyll metabolite, Pheophorbide A, is a known substrate of ABCG2 [42]. Upon 
binding to SMALP encapsulated ABCG2 a large increase was detected in the emission fluorescence 
of pheophorbide A (Figure 3C & Supplementary figure S2A). This increase was dose-dependent 
(Figure 3C), specific to ABCG2 (Supplementary figure S2B) and could be displaced by the ABCG2 
inhibitor chrysin (Figure 3C inset) with an IC50 of 3.7 µM, which is comparable with previous 
reports [43]. 
 
Nucleotide binding to purified Pgp encapsulated within SMALPs 
ABC transporters undergo nucleotide driven conformational changes to reorient substrate binding sites 
from high to low affinity conformations. For at least two of the transporters purified here it is ATP binding 
that provides this “power-stroke” [44, 45] and so we investigated whether the SMALP purified Pgp retained 
ATP binding. Figure 4 shows the quenching of intrinsic Pgp tryptophan fluorescence upon addition 
of either ATP or the fluorescent analogue TNP-ATP. The degree of tryptophan quenching and the 
affinity for TNP-ATP was much higher than for ATP itself, as has been reported previously [31, 
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46].The data were fit with a single site binding curve with a Kd for ATP of 0.49 ± 0.08 mM and for 
TNP-ATP of 84 ± 9 µM, which are comparable to previously reported values of 0.28 mM for ATP 
and 50.6 µM for TNP-ATP [31].  
 
Biophysical characterisation of Pgp encapsulated within SMALPs 
Next we wanted to characterise the biophysical properties of the purified ABC-SMALPs. For these 
studies we used Pgp as an example, because it is one of the best characterized ABC transporters 
[41]. The CD spectra shown in Figure 5A shows that the purified Pgp is folded, and the 
characteristic minima at 208 nm and 222 nm show that the structure is predominantly α-helical, as 
expected from recent structural studies [47, 48]. Analytical ultracentrifugation (Figure 5B) gives a 
single major peak showing that the Pgp within the SMALPs is monomeric. This is also shown with 
the gel filtration in Figure 5C, where the main peak corresponds to a molecular weight of approx 
164 kDa, in agreement with the predicted molecular weight (140 kDa unglycosylated). The gel 
filtration trace shows that the SMALP encapsulated Pgp does not show the levels of aggregation 
previously observed with dodecylmaltoside solubilised Pgp [39, 41].  
 
Cryo-electron microscopy (Figure 6) shows discrete particles of 5nm width and 15 nm length, 
consistent with monomers of Pgp. Classification of >8000 selected particles showed that the 
majority of particles were probably monomeric with a few classes indicating two Pgp particles 
associating to form hinge-shaped particles (Figure 6B).  An initial low resolution 3D structure 
(Figure 6C) produced from the single particles showed an envelope which was consistent with 
monomeric Pgp. Refinement of the structure (Figure 6D) was possible, generating a final (low) 
resolution of about 3.5nm (Figure 6E). The final structure was consistent with the published Pgp 
structure (3G5U) [49], although the resolution of the electron microscopy-derived structure did 
not allow unambiguous discrimination between the inward- and outward facing states (for 
example the outward-facing Sav1866 structure [50] could equally well be fitted within the low 
resolution envelope). Notably, the cryo-EM structure of Pgp within SMALPs lacks a large disc-
shaped belt, which might have been expected. However we have observed previously that the 
polymer itself shows almost no signal in unstained cryo-EM samples. Secondly it suggests the disc 
does not contain a large belt of lipid molecules, just a small annulus, which agrees with a previous 
study showing approximately 11 lipid molecules per protein [17]. 
 
Thermostability of Pgp encapsulated within SMALPs 
We surmised that the extraction of an ABC transporter with SMA, maintaining the lipid bilayer 
surrounding it, would not only preserve its structural integrity, but could also provide some 
advantages in terms of protein stability compared to detergent extraction.  To investigate this we 
examined the thermostability of purified Pgp encapsulated within SMALPs and compared it to Pgp 
solubilized using octyl glucoside as previously published [20].  Thermostability was monitored 
using the method of Alexandrov et al. [35] where reactivity with the fluorophore CPM was 
monitored over time as the temperature was systematically increased (Figure 7). This 
demonstrates that the Pgp-SMALP sample was significantly more stable than the detergent 
solubilised sample, with the apparent melting temperature increasing by more than 10 °C. 
 
Conclusion 
Until now the solubilisation and purification of ABC transporters has relied on the use of 
detergents to disrupt the membrane environment surrounding membrane proteins. This study has 
demonstrated that the polymer SMA can instead be used to extract eukaryotic ABC transporters 
from a wide range of different cell types and expression systems without the need for detergents. 
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The extracted proteins retain the ability to bind substrates and nucleotide and can be purified by 
affinity chromatography. This is important for two key reasons: firstly detergents are expensive 
and the requirement to supplement all purification buffers with detergent to maintain solubility 
can become financially limiting when scaling up procedures.  In contrast SMA is mass produced 
and can be used in a single step to form stable lipid disc structures that do not require addition of 
further polymer to any buffers. Secondly, and perhaps more importantly, the SMA method doesn’t 
disrupt the lipid environment surrounding a membrane protein in the way that detergents do. 
Instead a segment of membrane is extracted, and the native lipid bilayer surrounding a membrane 
protein is maintained.  
Furthermore the resultant purified transporters encapsulated within SMALPs are more pure, more 
stable and less prone to aggregation than detergent solubilised. It was also possible to concentrate 
the purified Pgp-SMALPs to > 8 mg/ml without significant loss of protein or aggregation.  
In the current study we have not attempted to demonstrate ATPase of SMALP purified ABC 
transporters, (although we have showed that the proteins retain their interaction with 
nucleotide), because the SMALP is destabilised by divalent metal ions. Reconstitution from the 
lipid disc structure into proteoliposomes will be required to fully characterise the ATP hydrolysis 
kinetics and this will also allow the measurement of substrate transport.  
However, as demonstrated by the work of Sligar and co-workers with nanodiscs, the small lipid-
disc structure is amenable to many different techniques [51]. The amphipathic polymer-based 
SMALPs do not suffer from signal interference from the apolipoprotein surrounding the lipid disc. 
Finally the EM structural data shows that there is not a large belt of lipids, and thus it may be 
compatible with structural studies such as cryo-electron microscopy and in principle could be used 
in 3D crystallisation trials. Thus this work opens up several new opportunities for the structural 
and pharmacological study of ABC transporters, and their annular lipid environment. 
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Figure legends: 
 
Figure 1. Extraction of ABC transporters using SMA polymer. Membrane preparations (30 mg/ml 
wet weight) were mixed with 2.5 %(w/v) SMA in 20 mM Tris pH8, 150 mM NaCl, 10 %(v/v) glycerol 
for 1 hour at room temperature, then centrifuged at 100,000 g for 20 min. Sample F also had 1 
%(w/v) DMPC added alongside the SMA, and was incubated at 37°C rather than room 
temperature. Samples of the soluble and insoluble material were assayed by Western blotting, 
and the percentage of the target protein in each was measured using densitometry.  
 
Figure 2. Purification of ABC transporters within SMA-lipid particles. A; SMA solubilised Pgp 
membranes (Sol) were incubated with Ni-NTA resin at 4°C overnight. Unbound material (FT) was 
removed and the resin was washed with buffer supplemented with 20-60mM imidazole before 
being eluted with buffer containing 120mM imidazole. Samples from each fraction were run on 
SDS-PAGE and silver stained. B-D; elution  fractions from purifications carried out as in A  but for 
ABCG2 (B), MRP4 (C) and CFTR (D).  E; QCRL-1 antibody was bound to a protein A column, then 
SMA  solubilised H69AR membranes were incubated with the column for 30 min at 20°C. Unbound 
proteins were washed out and MRP1 was eluted upon addition of the peptide SSYSGDI. 
 
Figure 3. Ligand binding assays. A; Purified Pgp-SMALPs were labelled with the fluorophore 
MIANS, then fluoresecence quenching upon binding of the inhibitor verapamil (open circles) and 
transport substrate doxorubicin (closed circles) were measured. B; Binding of 3H-estrone sulphate 
to SMA solubilised  H69AR membranes (MRP1) was measured in the presence and absence of 
3mM GSH (*P<0.05). E; Specific binding of  pheophorbide A to SMA-solubilised HEK-ABCG2 
membranes detected by an enhanced fluorescence of pheophorbide A at 681 nm. All data are 
mean±sem, n≥3. Inset; dose-dependent displacement of pheophorbide A binding by chrysin. 
 
Figure 4. Nucleotide binding to purified Pgp-SMALPs. Quenching of the intrinsic tryptophan 
fluorescence of purified Pgp (50µg/ml) within SMALPs upon binding of nucleotides (A) ATP and (B) 
TNP-ATP. Data are mean±sem and n≥3. 
 
Figure 5. Biophysical characterisation of purified Pgp-SMALPs. A; Circular dichroism spectra at 
0.65 mg/ml with a 0.1mm pathlength. B; Analytical ultracentrifugation trace. C; Gel filtration on a 
superdex 200 column (diameter 1.6cm, height 55cm), solid line is absorbance at 280nm, dashed 
line is conductivity.  
 
Figure 6. Structural characterisation of purified Pgp-SMALPs. A; Pgp particles solubilised in 
SMALPs and visualised (unstained)  using cryo-electron microscopy. The edge of the hole in the 
carbon support film of the electron microscopy grid is visible top right. The particles are 10-15nm 
diameter and are relatively monodisperse. B; Classification of the  particles reveals elongated 
particles of about 5nm width and 15nm length. Some classes appear to be formed by two particles 
associating. Box size is 21.6nm. C; An initial low resolution 3D envelope generated from single 
particle classes, and D; further refinement of the structure against all the raw particles. Orthogonal 
views are shown, with the ABCB1 crystal structure (3G5U) docked within it (blue ribbon). The 
refined structure was estimated to be at about 3.5nm resolution (E).  
 
Figure 7. Thermostability of purified Pgp. Purified Pgp (5 µg) was mixed with 8 µg/ml coumarin 
maleimide in a total volume of 200 µl  The reaction mixture was heated continuously from 10°C - 
90°C in increments of 5°C for 2 minutes each and the fluorescence spectra measured. 
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Fluorescence intensity (at 470nm) at each time point was calculated as a % of the final 
fluorescence intensity. Pgp was either solubilised with 2.5% SMA (open circles) or 2% octyl 
glucoside (closed circles). 
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Supplementary Information 
 
ABC protein 
(expression cell 
type) 
 
Yield of purified protein (µg) per 1L culture 
 SMA detergents 
 
Pgp/ABCB1 
(High Five) 
 
631 ± 46 
OGa 
792 ± 197 
DDMb 
249 ± 15 
 
 
ABCG2 
(High Five) 
 
116 ± 32 
 
FC-16c 
39 ± 14 
 
 
- 
 
MRP4/ABCC1 
(Sf9) 
 
 35 ±  3 
 
 
- 
 
- 
 
CFTR/ABCC7 
(S.cerevisiae) 
 
 
33 
 
DDMd 
67 
LPGd 
133 
 Yield of purified protein (µg) per 108 cells 
 
MRP1/ABCC1 
(H69AR) 
 
126 
 
CHAPSe 
250 
 
- 
 
Supplementary Table S1. Comparison of yield of purified protein using SMA or detergents 
The final yield of purified protein produced using SMA was calculated for each of the proteins 
studied per litre of cultured cells (Pgp, ABCG2, MRP4 and CFTR) or per 108 cells (MRP1).  Where 
errors are shown data are mean±sem, n≥3. For comparison yields previously obtained with these 
membranes using various different detergents are also shown. OG (octyl –β-D-glucoside), DDM 
(dodecyl-β-D- maltoside), FC-16 (foscholine-16), LPG (lysophosphatidylglycerol), CHAPS (3-(3-
cholamidopropyl)dimethylammonio-1-propanesulfonate).  
aTaylor et al (2001) Br J Pharmacol 134;1609-1618, R. Callaghan (personal communication) 
bPollock et al (2014) Biochim Biophys Acta 1838;134-47, R. Callaghan (personal communication) 
cMcDeviit et al (2006) Structure 14;1623-32, R. Callaghan (personal communication) 
dO’Ryan et al (2012) J Vis Exp 61, e3860, doi:10.3791-3860 
eMao et al (1999) Biochim Biophys Acta 1461;69-82. 
 
  
Supplementary Figure 1 
 
 
 
Figure S1. Comparison of MRP4 solubilisation and purification from Sf9 cells using SMA or 
detergent.A. Sf9-MRP4 membranes were solubilised in either 2.5 %(w/v) SMA, 2 %(w/v) DDM or 2 
%(w/v) OG for 1 hour and then centrifuged at 100,000g for 20min at 4°C. Samples of the soluble and 
insoluble material were assayed by Western blotting, and the percentage of the target protein in 
each was measured using densitometry.  B. Soluble material was incubated with Ni-NTA resin 
overnight at 4°C, transferred to a mini column and washed extensively with buffer supplemented 
with 20mM imidazole. Samples shown were eluted using 120mM imidazole. SDS-PAGE gels are silver 
stained. 
  
Supplementary Figure 2 
 
 
 
Figure S2. Enhanced fluorescence of pheophorbide A upon binding to ABCG2. A; Pheophorbide A 
(10 µM, 1 ml) fluorescence with an excitation wavelength of 390±10 nm, before (black) and after 
(red) a 10 minute incubation with ABCG2 containing SMA-solubilised membranes (40 µl). B; The 
increase in fluorescence emission at 681 nm of pheophorbide A (as in A) when SMA-solubilised 
membranes with overexpressed ABCG2, MRP1 or MRP4 are added, or when ABCG2 membranes are 
preincubated for 10 minutes with 30 µM chrysin. Data are mean±sem, n≥3. 
 
